Prnewswire·2026-01-27 14:25Core Viewpoint - Waters Corporation has received overwhelming shareholder approval for the issuance of shares to Becton, Dickinson and Company in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with the transaction expected to close on February 9, 2026 [1][2][3] Group 1: Shareholder Approval and Transaction Details - Approximately 99% of shares present at the Special Meeting voted in favor of the share issuance to BD shareholders [3] - The transaction has received all required regulatory approvals and a favorable Private Letter Ruling from the IRS regarding U.S. federal income tax consequences [2] - The expected closing date for the transaction is February 9, 2026, subject to customary closing conditions [2] Group 2: Future Outlook and Company Vision - The company aims to create meaningful value for patients, customers, employees, and shareholders as it transitions into a leader in life sciences and diagnostics [2] - The upcoming Q4 2025 financial results will be released on February 9, 2026, coinciding with the expected transaction close [4] - Waters Corporation has been a global leader in analytical instruments and technologies for over 65 years, serving various scientific fields [5]